Acute chest pain (ACP) is a common presenting symptom in clinical practice, posing a diagnostic challenge to clinicians due to its broad differential diagnosis. This article aims to provide a comprehensive approach to evaluating ACP, helping physicians to navigate through this clinical enigma.
The initial assessment should focus on identifying life-threatening conditions. The history should include the PQRST (Provocation, Quality, Region/Radiation, Severity, Timing) elements of pain. A thorough physical examination and an immediate electrocardiogram are essential. High-risk features such as older age, known coronary artery disease, and certain ECG changes should prompt immediate action.
When initial evaluation does not conclusively diagnose the cause of ACP, additional diagnostic testing is necessary. Cardiac biomarkers, chest X-ray, and computed tomography angiography (CTA) are commonly used. Cardiac stress testing and coronary angiography may be considered in certain scenarios. The choice of test should be guided by the pretest probability of disease, patient characteristics, and local resources.
Risk stratification is crucial in the management of ACP. Several validated risk scores exist, such as the TIMI (Thrombolysis in Myocardial Infarction) and GRACE (Global Registry of Acute Coronary Events) scores. These can aid in decision-making regarding the need for hospital admission and the intensity of treatment.
Management of ACP is guided by the underlying cause. For suspected acute coronary syndrome (ACS), early initiation of antiplatelet and anticoagulant therapy is recommended. Non-cardiac causes of ACP should be managed appropriately based on the specific diagnosis.
Evaluating ACP is a complex task requiring a systematic approach. By conducting a thorough initial assessment, utilizing appropriate diagnostic testing, performing risk stratification, and implementing evidence-based management strategies, clinicians can effectively navigate this clinical challenge and optimize patient outcomes.
1.
We Don't Always Know What's 'Best' for Our Patients
2.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
3.
DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.
4.
Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.
5.
AI Framework Helps Classify Renal Tumors, Predict Outcomes
1.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
2.
The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies
3.
Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment
4.
IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights
5.
Survivorship Care Planning Beyond Active Cancer Treatment: Advancing Care Continuity for Cancer Survivors
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
4.
Innovations in Hematology
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation